New Leaf Ventures is a company.
Key people at New Leaf Ventures.
New Leaf Ventures was founded by Josh Yelen (Co-Founder and Partner).
Key people at New Leaf Ventures.
New Leaf Venture Partners (NLVP) is a New York-based venture capital firm exclusively focused on healthcare technology, investing in exceptional entrepreneurs revolutionizing the sector through biopharmaceuticals, information convergence, and life science tools.[1][3][4] Their mission centers on leveraging innovation to advance healthcare by funding visionary teams developing therapies tailored to patient biomarkers, technology-driven efficiency tools, and research accelerators that improve patient outcomes and reduce system burdens.[3] With a philosophy rooted in deep technical, operational, and clinical expertise, NLVP provides hands-on support to build leading companies, managing over $500 million across funds and boasting 222 investments and 55 portfolio exits.[2][3]
NLVP significantly impacts the startup ecosystem as a leader in healthcare VC, particularly in later-stage biopharma products, early-stage medical devices, and lab infrastructure, fostering breakthroughs in areas like personalized medicine and digital health.[1][2][3]
Founded in 2005 as a healthcare spinoff from the Sprout Group—one of the oldest U.S. venture capital funds—New Leaf Venture Partners emerged to specialize in healthcare technology amid growing demand for biotech and medtech innovation.[2] Key partners bring blended technical, operational, and clinical experience, enabling close collaboration with entrepreneurs to scale companies from early ideation to public markets.[2][3] The firm's focus has evolved from broad healthcare investments (including IT, biopharma, and devices) to an exclusive emphasis on transformative healthcare tech, marked by pivotal portfolio successes in both private and public arenas.[2][3]
New Leaf rides the wave of healthcare innovation driven by precision medicine, AI-enabled diagnostics, and digital therapeutics, capitalizing on post-pandemic acceleration in biotech funding and regulatory tailwinds for personalized treatments.[2][3] Timing is ideal amid aging populations, rising costs, and tech convergence (e.g., biomarkers and data analytics), positioning NLVP to back companies addressing unmet needs in patient care and R&D efficiency.[3] Market forces like biomarker validation and life sciences digitization favor their portfolio, while NLVP influences the ecosystem by nurturing high-impact startups (e.g., Cleerly, Edgewise Therapeutics) that set standards for tailored therapies and tools.[3]
NLVP is poised to expand influence in AI-biotech hybrids and next-gen diagnostics, with trends like multimodal data integration and gene editing shaping their next investments amid a maturing healthcare VC rebound.[2][3] Expect deeper Series B/C bets on resilient portfolios like Qlaris Bio and Abcuro, evolving from spinoff origins to a dominant force in funding tomorrow's healthcare leaders—continuing to revolutionize the sector one exceptional entrepreneur at a time.[3]
New Leaf Ventures was founded by Josh Yelen (Co-Founder and Partner).
